Longitudinal and case studies focused on the therapeutic potential of adalimumab (monoclonal anti-TNF-α antibody) have determined that more than half of severe HS patients will have symptom alleviation after treatment (reduction in the number of affected areas); however, the relapse rate is just as high if patients decide to discontinue treatment. This evidence concerns the gene TNF and histiocytic sarcoma.